Pharmaceutical Sciences Faculty Publications

The Proteomics of Neurodegeneration

Document Type

Article

Publication Date

1-1-2005

Journal Title

American Journal of Pharmacogenomics

ISSN

1175-2203

Volume

5

Issue

4

First Page

259

Last Page

270

DOI

10.2165/00129785-200505040-00006

PubMed ID

16078862

Abstract

The continuing improvement and refinement of proteomic and bioinformatic tools has made it possible to obtain increasing amounts of structural and functional information about proteins on a global scale. The emerging field of neuroproteomics promises to provide powerful strategies for further characterizing neuronal dysfunction and cell loss associated with neurodegenerative diseases. Neuroproteomic studies have thus far revealed relatively comprehensive quantitative changes and post-translational modifications (mostly oxidative damage) of high abundance proteins, confirming deficits in energy production, protein degradation, antioxidant protein function, and cytoskeletal regulation associated with neurodegenerative diseases such as Alzheimer and Parkinson disease. The identification of changes in low-abundance proteins and characterization of their functions based on protein-protein interactions still await further development of proteomic methodologies and more dedicated application of these technologies by neuroscientists. Once accomplished, however, the resulting information will certainly provide a truly comprehensive view of neurodegeneration-associated changes in protein expression, facilitating the identification of novel biomarkers for the early detection of neurodegenerative diseases and new targets for therapeutic intervention.

Keywords

Alzheimer disease, Down syndrome, glutamine, motor neuron disease, neurodegenerative diseases, Parkinson disease, proteomics, trauma, nervous system, tau proteins

Link to Full Text

Share

COinS